cyrilzakka/clinical-trials huggingface dataset:
Medium Chain Triglycerides and Brain Metabolism in Alzheimer's Disease

Evaluate and compare the changes in brain ketone and glucose uptake after taking two different MCT oil emulsions (60-40 oil or C8 oil) for one month, in a group of people with Alzheimer's disease and a control group.

Based on a PET/MRI protocol, the aim of this study is to evaluate and compare the response to the dietary supplementation of two different MCT oils (60% C10 + 40% C8 or 100 % C8) in two groups, patients with Alzheimer's disease and healthy elderly people (N=10/group). After a baseline evaluation, participant will test one of the supplements during two successive periods of one month; each period of time ending with 18F-FDG and 11C-acetoacetate PET scans.

Eligibility Criteria:
Inclusion Criteria:

* Good general health for Control group
* Diagnosis of Alzheimer's disease (NINCDS-ADRDA criteria) for AD group

Exclusion Criteria:

* Depression
* Medical or psychiatric conditions that could interfere with study participation
* Fasting plasma glucose ≥7.0 mM (diabetes or prediabetes)
* Already on MCT supplementation
* Clinically-significant gastrointestinal disease/conditions
* Clinically-significant liver disease/dysfunction
* Clinically-significant renal disease/dysfunction
* Clinically-significant cardiac disease/conditions
* Hypertension
* Uncontrolled dyslipidaemia
* Vitamin B12 deficiency
* Structured physical activity (more than 3 times/week)
Salivary Cortisol in Intensive Care Unit

In critical illness, patients are highly stressed and should have elevated cortisol (stress hormone) secretion to adapt to stress. Dysfunction of this system is referred to as critical illness-related corticosteroid insufficiency. Free cortisol (unbound form) which is mainly responsible for its physiologic function is difficult to measure. We hypothesized that the salivary cortisol, which can be obtained by noninvasive methods, can more accurately evaluate adrenal function of critically ill patients.


Eligibility Criteria:
Inclusion Criteria:

* patients who agreed to participate

Exclusion Criteria:

* Known adrenal or pituitary disease
* oral bleeding
* currently on systemic or inhaled corticosteroids
Determinants of the Long-Term Success of Bariatric Surgery

The management of obesity is based on a multidisciplinary approach and justifies the use of surgery in patients with the most severe forms. Surgery for obesity or bariatric surgery generally allows rapid and significant weight loss however it is associated with significant risks, and its long-term results remain heterogeneous and unpredictable. Long-term data will clarify the role of different types of bariatric surgery in surgical strategy, improve patient information and identify predictors of failure in order to provide personalised and tailored surgery for each candidate .

Currently, there is insufficient data to determine the persistence over time of the positive results of bariatric surgery on weight loss. Moreover, there is no consensus or criteria for choosing one surgical weight loss procedure over another. The best choice for one patient may not be the most appropriate for another.

The results of this project will allow to better select obese patients likely to benefit from bariatric surgery, and to further personalise the management of severe obesity.

Eligibility Criteria:
Inclusion Criteria:

* Patients who received bariatric surgery 5 years ago.

Exclusion Criteria:

* Refusal to participate in the study,
* Unable to receive informed information,
* Unable to participate in the study
Catheter-Directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis

Deep vein thrombosis (DVT) is a severe disease, and conventional treatment with low molecular weight heparin (LMWH) and warfarin is associated with some degree of long-term sequelae, i.e. post-thrombotic syndrome (PTS). Catheter-directed thrombolytic (CDT) therapy has been introduced worldwide the last two decades. Reports have suggested a beneficial effect of this costly treatment, but there are no randomized clinical trials documenting its short- and long-term efficacy and safety. This multi-center study will randomize patients with acute iliofemoral vein thrombosis to either conventional treatment or CDT in addition to conventional treatment. Main outcome parameters are patency rates at 6 months and prevalence of PTS at 24 months. The main short-term hypothesis is that CDT of first-time acute DVT will increase patency of the affected segments after 6 months from \<50% to \>80%. The main long-term hypothesis is that CDT will improve long-term functional outcome, i.e. risk of PTS after 2 years from \>25% to \<10%.


Eligibility Criteria:
Inclusion Criteria:

* Onset of symptoms \<21 days
* Objectively verified DVT of the femoral or common iliac veins or the combined iliofemoral segment
* Informed consent

Exclusion Criteria:

* Anticoagulant therapy prior to trial entry \>7 days
* Contraindications to thrombolytic therapy
* Indications for thrombolytic therapy, i.e. phlegmasia coerulea dolens or vena cava thrombosis
* Severe anemia, hemoglobin (hgb)\<8 g/dl
* Thrombocytopenia, platelets \<80x10\^9/l
* Severe renal failure, creatinine clearance \<30ml/min
* Severe hypertension, systolic (syst) blood pressure (BP)\>160 mmHg or diastolic (diast) BP \>100 mmHg pregnancy
* Less than 14 days post-surgery or post-trauma
* History of subarachnoidal or intracerebral bleeding
* Disease with life expectancy \<24 months
* Drug abuse or mental disease that may interfere with treatment and follow-up
* Former ipsilateral proximal DVT
* Chemotherapy or advanced malignant disease
Gaze Contingent Feedback in Social Anxiety Disorder

The purpose of this study is to determine whether giving gaze-contingent feedback is an effective attention modification procedure, helping in the treatment of social anxiety disorder (SAD)

The study examines giving social anxious participants gaze-contingent feedback as a novel attention training procedure. Half of the participants will receive contingent feedback while the other half would receive non-contingent "placebo" feedback.

Eligibility Criteria:
Inclusion Criteria:

* A signed consent form
* Men and women between the ages of 18 and 60.
* Meeting a current diagnosis of Social Anxiety Disorder (SP) according to the DSM-IV
* A minimum of a 1-year duration of SP
* SP as the primary diagnosis: In cases of co-morbidity, SP will be deemed as the most distressing and clinically significant condition among the co-morbid disorders
* Stable pharmaco-therapy: Participants receiving a pharmacological treatment who are taking a stable medication for at least 3 months before the beginning of the procedure.

Exclusion Criteria:

* Psychotic episode in the past or the present time.
* Co-morbidity with any neurological disorder (i.e., epilepsy, brain injury).
* Another psychotherapeutic treatment during the study.
* Usage of neuroleptic medication.
* Change in medication status during the study.
* Substantial usage of drugs or alcohol in the present time.
* Poor judgment capacity (i.e., children under 18 and special populations).
Mechanism of Weight Loss After Endoscopic and Laparoscopic Sleeve Procedures

The purpose of this research study is to understand the mechanism of weight loss for weight loss procedures: that is Laparoscopic sleeve gastrectomy and Endoscopic sleeve Gastroplasty.

We want to better understand the mechanisms for weight loss by understanding the anatomic and physiologic changes that occur with gastric restrictive procedures for weight loss and to determine the differences in metabolic profile between the two restrictive procedures. We also want to identify the rate of Gastro Esophageal Reflux Disease (GERD) in patients undergoing gastric restrictive procedures for weight loss.

Eligibility Criteria:
Inclusion Criteria:

1. BMI ≥ 30 Kg/m2 scheduled to undergo a bariatric intervention
2. Patients who will be undergoing ESG or LSG as part of their clinical care Age between 18 and 75 years.
3. Both male and female subjects will be included in the study.
4. Subjects from any ethnic background will be included in the study.
5. Female participants of childbearing age should not be pregnant. (Pregnancy test will be performed on all women of child bearing potential before any standard of care endoscopic procedure. For the purpose of the study we will record that information in the patient study records).
6. Successfully complete the screening process.
7. Patients able to provide written informed consent on the IRB/EC-approved informed consent form.
8. Demonstrate willingness to follow protocol requirements, including follow-up schedule, and completion of questionnaires.
9. Having standard of care therapy (endoscopic or laproscopic) for treatment of Obesity.

Exclusion Criteria:

1. Pregnant or planning to become pregnant during period of study participation.
2. Female participants who are breast-feeding.
3. Severe Immunodeficiency.
4. Severe malnutrition.
5. The participant has life expectancy of less than 1 year due to other medical conditions.
Comparison of Serum SIRT-1 and MMP-9 Levels of Patients With Bronchiectasis and Healthy Controls

The purpose of this a cross-sectinol study is to measure the levels of MMP-9 and SIRT-1 levels in patients with bronchiectasis and healthy controls. The aim is to compare the serum levels of these molecules between patients and controls.

* Is the MMP-9 level increasing or decreasing?
* Is the SIRT-1 level increasing or decreasing in patients?
* Is the disease related to age and gender? Participants will only have one 5 ml blood sample drawn when they visit the chest illness clinic. Molecule levels will be measured in this blood's serum.

The patient group participants will be scanned once with high-resolution chest CT.

Apart from this, comparisons will be made using the age and gender information of the participants.

In the overall study population of 60 subjects who applied to the Sivas Cumhuriyet University Faculty of Medicine Research and Practice Hospital Chest Diseases Clinic. The study population was selected regardless of age and gender. Participants selected bronchiectasis patients (n=30) who had symptoms (cough, sputum production) and had their diagnosis confirmed by a chest high-resolution CT scan within the previous year. The study excluded individuals with bronchiectasis not associated with cystic fibrosis and who had a worsening episode (according to the 2017 European Respiratory Society expert consensus criteria) (16) or had taken antibiotics during the previous four weeks. The study enrolled healthy controls (n=30) through advertisements who had acceptable chest X-ray and spirometry results and no lower airway symptoms or serious systemic disorders. The study eliminated individuals who were pregnant or nursing, as well as those with low comprehension. SIRT-1 and MMP-9 levels in the serum of the study group were determined by the ELISA method.

Eligibility Criteria:
Inclusion Criteria:

* Bronchiectasis patients who were symptoms (cough, sputum production)
* Individuals whose diagnosis was confirmed by a high-resolution chest CT scan taken within the previous year

Exclusion Criteria:

* Individuals with bronchiectasis associated with cystic fibrosis and who had a worsening episode
* individuals who were pregnant or nursing
* those with low comprehension
* taken antibiotics during the previous four weeks
National Survey Among Egyptian Pain Practitioners

Coronavirus pandemic health restrictions has deleteriously affected the rates of all interventional procedures even for emergency cases. This study tried to evaluate the impact of the outbreak of SARS-CoV-19 infection on rates of interventional pain therapy (IPT).

Background: Coronavirus pandemic health restrictions has deleteriously affected the rates of all interventional procedures even for emergency cases. This study tried to evaluate the impact of the outbreak of SARS-CoV-19 infection on rates of interventional pain therapy (IPT).

Methods: Setting: Multicenter Study. Design: Prospective observational study, approved by the Local Ethical Committee (RC:2-1-21). Materials: Two 20-item questionnaires with five choices for probable answer using a Likert-5 point scale were constructed as self-assessment questionnaire. The questionnaires were uploaded to the Google drive, and the links and identification codes were sent using the WhatsApp to 500 IPT providers. The feedback answers were scored and statistically analyzed. Statistical analyses will be performed using IBM® SPSS® Statistics (Version 22, 2015; Armonk, USA) for Windows statistical package. P value \<0.05 was considered statistically significant.

Eligibility Criteria:
Inclusion Criteria:

registered pain practitioners in Egypt.

-

Exclusion Criteria:

Non registered pain practitioners
Effect of Korean Red Ginseng on Central Blood Pressure in Patient With Essential Hypertension

The purpose of this study is to determine Korean red ginseng (KRG)treatment could decrease central blood pressure in subjects with hypertension.

Participants with hypertension who were treated with antihypertensive agents were randomly assigned to an active (KRG 2 g/day) or a placebo treatment group in a double-blind cross over manner.

Participants were not allowed to change their antihypertensive medications except safety issue. Brachial systolic BP (SBP), diastolic BP (DBP), Central SBP and DBP will measured at baseline,at 2 and 4 months.

Efficacy and safety data will be monitored by Daegu Catholic University Medical Center Institutional Review Board and reported to the Korean Ginseng Society.

Eligibility Criteria:
Inclusion Criteria:

* Essential hypertension
* diastolic blood pressure 100 mmHg or less and systolic blood pressure 160 mmHg or less

Exclusion Criteria:

* Secondary hypertension
* Serum creatinin above 1.5 mg/dL
* aspartate aminotransferase(AST) and alanine aminotransferaseALT above two times upper normal limits
* Uncontrolled diabetes (Hb A1c \< 9%)
* Acute myocardial infarction or coronary artery disease intervention within six months
* Moderate to severe congestive heart failure
* HIV positive
* Immunocompromized host
* Allergy to Korean red ginseng
* Pregnancy or plan to pregnancy
* Alcohol or drug abuse
* Attend to other clinical trial within 12 weeks
STUDY of the SAFETY and EFFICACY of MOXIDECTIN TABLETS for the REDUCTION of DEMODEX EYELASH INFESTATION

A Single-Center, Investigator-Masked, Randomized, Placebo-Controlled, Investigator Initiated Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash Infestation


Eligibility Criteria:
Inclusion Criteria: Active blepharitis with collarettes -

Exclusion Criteria:Other clinically significant eye disease

-
Probiotics and Health-related Quality of Life in Individuals With Seasonal Allergies

In this randomized, double-blind, placebo-controlled study, participants with seasonal allergies will receive a daily probiotic or placebo for 8 weeks. Questionnaires will assess health-related quality of life, stress, physical activity, gastrointestinal symptoms, adverse events, and compliance. In a subset of subjects, stool and blood samples will be collected at baseline and at week 6 of the intervention (estimated to be peak allergy season) to characterize microbial communities and immune function.


Eligibility Criteria:
Inclusion Criteria:

Subjects will be included if they:

* are 18 to 60 years of age (inclusive).
* receive a score of 2 or greater on the Mini Rhinoconjunctivitis Quality of Life Questionnaire.
* are willing and able to complete the Informed Consent Form in English.
* are available for 8 consecutive weeks to participate in this study.
* be willing and able to complete online daily and weekly questionnaires regarding general wellness, bowel function, quality of life, gastrointestinal symptoms, and physical activity.
* are willing and able to maintain their regular level of physical activity and diet for the 8-week study.
* are able to take the study supplement without the aid of another person.
* are willing to discontinue consumption of fermented foods or probiotics (e.g., yogurts with live, active cultures or supplements), or immune-enhancing supplements (e.g., Echinacea or fish oil).
* are willing to provide 2 blood and 2 stool samples (subgroup only).

Exclusion Criteria:

Subjects will be excluded if they:

* do not meet any of the above criteria.
* use allergy medications, including nasal sprays, 5 or more days per week.
* receive allergy shots.
* are currently pregnant or attempting to get pregnant.
* are currently taking any systemic corticosteroids, androgens (such as testosterone), or large doses of anti-inflammatory drugs (i.e., aspirin in doses \>600 mg/d) on a regular basis.
* are currently being treated for or have any of the following physician-diagnosed diseases or conditions: HIV/AIDS; immune modulating diseases (autoimmune disease, hepatitis, cancer, etc.); kidney disease; pancreatitis; pulmonary disease; hepatic or biliary disease; or gastrointestinal diseases/conditions such as diverticulitis, ulcerative colitis, Crohn's disease, Celiac disease, short bowel disease, ileostomy, or colostomy, but not including GERD; or have a central venous catheter.
* have received chemotherapy or other immune suppressing therapy within the last year.
Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection

Clostridioides difficile infection (CDI) is one of the most common hospital-acquired infectious diseases with a high mortality rate (6-30%). The treatment of CDI, especially the recurrent form of the disease is still considered a challenge. The FILTRATE randomized controlled trial aims to investigate the safety and efficacy of fecal filtrate transplantation in the treatment of recurrent CDI and compare it with conventional fecal microbiota transplantation (FMT).

The treatment of recurrent CDI is still a burden on the healthcare system. FMT is highly effective for the treatment of recurrent CDI, resulting in the resolution of CDI up to 100% of the cases. FMT also has a good short-term safety profile, however long-term events like transfer of multiresistant bacteria and other living microorganism is still a major problem. On the other hand, the fecal filtrate contains only bacterial debris, proteins, and antimicrobial compounds and not intact microorganisms.

The FILTRATE trial is a multicenter, two-arm randomized controlled trial, and aims to compare the safety and efficacy of fecal filtrate transplantation to conventional fecal microbiota transplantation (FMT) in the treatment of recurrent CDI. Adult patients with multiple recurrent (\>1) CDIs will be randomized 1:1 to receive either FMT or fecal filtrate transplantation. The transplantation will be carried out using lyophilized capsule on each arm. The primary endpoint of the study will be the clinical resolution of CDI-associated diarrhea 8 weeks after the interventions. Questionnaires will be completed on enrollment and at the time of each follow-up. Adverse events will be recorded and reported to the relevant institutional and national ethics committee. After the intervention, a one-year follow-up is also planned. Blood and stool samples will be collected at baseline and at each follow-up.

Eligibility Criteria:
Inclusion Criteria:

* age ≥18 years
* multiple recurrent CDI (≥2 previous episodes of CDI)
* at least 3 or more loose or watery stools (Bristol 5-7) per day
* a positive Glutamate Dehydrogenase (GDH)-enzyme and positive CDI toxin A and/or B test
* the patient or the legal guardian sign the written informed consent

Exclusion Criteria:

* pregnancy or breastfeeding
* ongoing antibiotic treatment
* fulminant CDI
* previous FMT
* immunodeficiency
* need of intensive care
* requirement for vasoactive drugs
* other cause of diarrhea
* inflammatory bowel diseases
* irritable bowel syndrome
* life expectancy shorter than 3 months
* unavailable for follow-up visits
Diabetes Mellitus and Pregnancy : Knowledge Assessment

Diabetes, a chronic and frequent disease, is a risk factor of pregnancy complications such as preeclampsia, congenital malformations and macrosomia.

Preconception care is all methods to assess the best prognostic for a diabetic pregnancy. Among these methods, contraception is very important to plan the pregnancy on a chosen moment.

The content of the preconception care is well established. However, information of diabetic women concerning contraception and giabetic pregnancy has been little studied.

The aim of the study is to describe the knowledge of the patients with diabetes concerning contraception and pregnancy planning.

Eligibility Criteria:
inclusion criteria :

* Patients Aged between 18 and 40 years old
* With type 1 or type 2 diabetes mellitus
* Consulting in the department of diabetology in Reims and Charleville Mezieres hospitals
* Accepting to participate in the study

exclusion criteria :

* Patients With secondary diabetes (endocrine, pancreatic or genetical origin)
* With postmenopausal status
* Without capacity to have a pregnancy (uterine aplasia, hysterectomy)
Clinical Features, Outcomes, and Therapeutics of Pregnancy-Related Aortic Dissection

Aortic dissection in pregnancy represents a lethal risk to both the mother and fetus, it has yet to yield the optimal therapeutic strategy. The aim of this study was to characterize the clinical features and outcomes in women with pregnancy-related acute aortic dissection, and to suggest therapeutic guidelines.


Eligibility Criteria:
Inclusion Criteria:

* Women who presented with aortic dissection during pregnancy or post partum ≤12 weeks.

Exclusion Criteria:

* Loss of surgical information.
Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients

This study evaluates generic emtricitabine(FTC) in Chinese naive children chronic hepatitis B patients. Single group of child patients were enrolled, which include HBeAg positive and negative Chronic hepatitis B(CHB)group.

Generic emtricitabine(FTC) has been approved for treatment of naive chronic hepatitis B(CHB) patients in China. Yet data are limited for this agent in children paitients. The investigators design this trial to test the effect of FTC in Chinese children CHB which including naive HBeAg positive and Negative CHB patients.

Eligibility Criteria:
Inclusion Criteria:

* Children with body weight ≥ 33 kg and who can swallow entire emtricitabine capsle(200mg)
* HBsAg positive for more than 6 months
* HBeAg positive patients: HBV DNA ≥ 5log10 copies/ml
* HBeAg positive patients: ALT≥2×ULN;or liver biopsy G≥2;or liver biopsy S ≥2;or liver biopsy Knodell HAI ≥ 4
* HBeAg negative patients: HBV DNA ≥ 4log10 copies/ml
* HBeAg positive patients: ALT≥2×ULN;or liver biopsy G≥2;or liver biopsy S ≥2;or liver biopsy Knodell HAI ≥ 4
* Nucleoside/nucleotide naive patients

Exclusion Criteria:

* - Diagnosed HCC with AFP and ultrasound, CT or MRI
* Creatine \>130μmol/L or Ccr \< 70mL/min
* Hemoglobin \<100g/L
* Neutrophils \<1.5E+9/L
* PLT\<80E+9/L
* Coinfected with HAV,HEV,HCV,HDV or HIV
* ANA \> 1:100
* Uncontrolled cardiovascular diseases, kidney diseases,lung diseases, neurological diseases, digestive diseases,metabolic disorders, immune-compromised diseases or cancer
* Drug abuse or alcohol addiction
* Previous history of taking agents of lamivudine, adefovir, tenofovir entecavir or telbivudine
* Long-term use of immunosuppressor or immunomodulator 6 months before enrollment to this trial
* Underwent liver transplantation or liver transplantation in schedule
* Allergic to nucleoside or nucleotide analogues
* Pregnancy or in breastfeeding